The
trans
cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells
Supplemental Material
Supplemental_Figures.pdf
Supplemental_Legends.pdf
Supplemental_Table1.pdf
Supplemental_Table2.pdf
Supplemental_Table3.pdf